Deucravacitinib could be an effective and safe choice in patients affected with psoriasis and atopic dermatitis (Psorema)?

Edoardo Cammarata; Federica Veronese; Paola Savoia

doi:10.23736/S2784-8671.25.08277-5

Deucravacitinib could be an effective and safe choice in patients affected with psoriasis and atopic dermatitis (Psorema)?

Edoardo Cammarata
, Federica Veronese
, Paola Savoia

Department of Health Sciences

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	76-77
Number of pages	2
Journal	Italian Journal of Dermatology and Venereology
Volume	161
Issue number	1
DOIs	https://doi.org/10.23736/S2784-8671.25.08277-5
Publication status	Published - Feb 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.23736/S2784-8671.25.08277-5

Cite this

@article{0c97a703bc5e46fd9c21f8284e6cb0c0,

title = "Deucravacitinib could be an effective and safe choice in patients affected with psoriasis and atopic dermatitis (Psorema)?",

author = "Edoardo Cammarata and Federica Veronese and Paola Savoia",

year = "2026",

month = feb,

doi = "10.23736/S2784-8671.25.08277-5",

language = "English",

volume = "161",

pages = "76--77",

journal = "Italian Journal of Dermatology and Venereology",

issn = "2784-8671",